

References

1. Aviram M. Does paraoxonase play a role in susceptibility to cardiovascular disease? *Mol Med Today*. 1999 Sep;5(9):381–6.
2. Bilora F, Sartori MT, Zanon E, Campagnolo E, Arzenton M, Rossato A. Flow-Mediated arterial dilation in primary antiphospholipid syndrome. *Angiology* 2009;60:104–7.
3. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. *Lancet*. 1992;340:1111–5.
4. Cervera R, Khamashta M, Shoenfeld Y, Camps M, Jacobsen S, Kiss E, Zeher M, Tincani A, Kontopoulou-Griva I, Galeazzi M, Bellisai F, Meroni P, Derksen R, de Groot P, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris J, Que´re I, Hachulla E, Vasconcelos C, Roch B, Fern´andez-Nebro A, Piette J, Espinosa G, Bucciarelli S, Pisoni C, Bertolaccini M, Boffa M, Hughes G , on behalf of the Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies) Morbidity and mortality in the antiphospholipid syndrome during a 5-year period:a multicentre prospective study of 1000 patients. *Ann Rheum Dis* 2009;68:1428–1432.
5. Conroy R, Pyorala K, Fitzgerald A, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetie`re P, Jousilahti P, Keil U, Njulstad I, Oganov R, Thomsen T, Tunstall-Pedoe H, Tverda A, Wedel H, Whincup P, Wilhelmsen L, Graham I. on behalf of the SCORE project group1 Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. *Eur Heart J* 2003;24:987–1003.
6. Chung CP, Oeser A, Avalos I, Raggi P, Stein CM. Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus. *Lupus* 2006;15(9):562–9.
7. Espinosa G, Cervera R. Antiphospholipid syndrome: frequency, main causes and risk factors of mortality. *Nat Rev Rheumatol*.2010;6:296–300.
8. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1997;40:1725–34.
9. Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. *Am J Cardiol*. 1976 Jul;38(1):46–51.
10. Kawai, Vivian K., Solus, Joseph F., Oeser, Annette, Rho, Young Hee, Raggi, Paolo, Bian, Aihua, Gebretsadik, Tebeb A New 30-Year Cardiovascular Risk Prediction Score Does Not Differ in Women with Systemic Lupus Erythematosus and Control Subjects. *Arthritis & Rheumatism*, Volume 63, November 2011 Abstract Supplement Abstracts of the American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting Chicago, Illinois November 4-9, 2011.
11. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *J Thromb Haemost* 2006;4:295–306.
12. New studies outline cardiovascular risk in lupus patients By: JENNIE SMITH, Internal Medicine News Digital Network 05/09/13[electronic sours] This page was printed from www.InternalMedicineNews.com . For reprint inquires, call 877-652-5295, ext. 102.

13. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. *JAMA* 2007;297:611–619.
14. Ridker PM, Paynter NP, Rifai N. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. *Circulation*. 2008;118:2243–2251.